Highest-materiality recent filing
XBiotech CEO John Simard retires; CSO Sushma Shivaswamy named interim CEO
John Simard retired as CEO/President effective Dec 8, 2025; continues as Chairman.
XBiotech amends director bio: Rademaker is consultant to multiple PE firms
Clarifies Craig Rademaker is a consultant to several Canadian private equity firms, not a single firm.
XBiotech enters new employment agreement with CEO John Simard; $1.25M salary, $4.53M bonus baseline
Base salary unchanged at $1.25M; annual bonus baseline set at $4.53M for 2025, both inflation-adjusted annually.
XBiotech Inc. Announces Results of Annual Meeting of Stockholders
Elected five directors: John Simard (12.37M for), Thomas Kündig (12.70M), Craig Rademaker (12.50M), Tevi D. Troy (12.30M), David Soffer (12.30M).
XBiotech appoints Dr. Thomas Kündig and Craig Rademaker to Board of Directors
Dr. Thomas Kündig, Director of Dermatology at University Hospital Zurich, appointed to Board and Compensation Committee effective June 24, 2025.
W. Thorpe McKenzie retired from the Board effective March 27, 2025.
Director W. Thorpe McKenzie retires from XBiotech board effective March 27, 2025
McKenzie served since 2009; was on Audit, Compensation, and Nominating Committees.
XBiotech appoints renowned immunologist Dr. Tak W. Mak to its Board of Directors
Dr. Mak appointed December 24, 2024 to fill board vacancy; will serve until next annual meeting.
XBiotech stockholders elect five directors and ratify auditor at annual meeting
Proposal 1: Five directors elected; John Simard received 9,032,922.58 votes for, Jan-Paul Waldin 7,407,212.58, W. Thorpe McKenzie 8,485,018.58, Donald MacAdam 8,817,755.58, Peter Libby 9,040,330.58.
XBiotech enters $10M convertible loan from CEO to fund new R&D facility
$10M loan from CEO John Simard at 8% simple interest, secured by real estate and cash.
XBiotech annual meeting elects five directors; auditor ratified
John Simard, Jan-Paul Waldin, W. Thorpe McKenzie, Donald MacAdam, and Peter Libby re-elected as directors.
XBiotech appoints Angela Hu as principal financial and accounting officer, replacing Queena Han
Angela Hu, formerly Financial Controller, becomes principal financial and accounting officer effective February 10, 2023.
XBiotech stockholders elect five directors and ratify auditor at 2022 annual meeting
John Simard re-elected with 10,345,079 for, 154,052 abstentions, 1,766,205 broker non-votes.
XBiotech dismisses Ernst & Young, appoints Whitley Penn as auditor for FY 2022
Audit committee appointed Whitley Penn LLC as independent registered public accounting firm for fiscal year ending Dec 31, 2022.
XBiotech extends clinical manufacturing agreement with Janssen through December 2023
XBiotech entered a Manufacturing Agreement with Janssen R&D to produce clinical product including Bermekimab.
XBiotech declares special cash dividend of $2.50 per share ($75M total)
Extraordinary cash dividend of approx $2.50/share, aggregate up to $75M.
On March 27, 2025, W. Thorpe McKenzie informed the Board of Directors (the “Board”) of XBiotech Inc. (the “Company”) via letter of his decision to retire from the Board, effective immediately.
Queena Han, whose employment as Vice President, Finance and Human Resource ended on February 3, 2023.
On February 10, 2023, Angela Hu, who presently serves as the Financial Controller of XBiotech Inc. (the “Company”), assumed the role as the Company’s principal financial officer and principal accounting officer.
Max materiality 0.70 · Median 0.40 · Most common event leadership